

Cholera Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CE290E1A2351EN.html>

Date: March 2022

Pages: 56

Price: US\$ 2,000.00 (Single User License)

ID: CE290E1A2351EN

Abstracts

Cholera Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Cholera (Infectious Disease) pipeline landscape.

Cholera is an acute infectious disease caused by a bacterium, *Vibrio cholera*, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Often symptoms are mild. But sometimes they are very serious. Signs and symptoms of Cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated, this can lead to shock and death in a matter of hours.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cholera - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Cholera (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Cholera (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Discovery stages are 2, 1, 2, 1 and 2 respectively. Similarly, the Universities portfolio in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 1, 4 and 2 molecules, respectively.

Cholera (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Cholera (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Cholera (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Cholera (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Cholera (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Cholera (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Cholera (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Cholera (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Cholera - Overview
- Cholera - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Cholera - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Cholera - Companies Involved in Therapeutics Development
- Bharat Biotech Ltd
- Emergent BioSolutions Inc
- Global BioLife Inc Ltd
- Napo Pharmaceuticals Inc
- Ostrich Pharma USA Inc
- SOM Biotech SL
- Vanda Pharmaceuticals Inc
- Cholera - Drug Profiles
- Antibodies for Cholera - Drug Profile
- Product Description
- Mechanism Of Action
- bevantolol - Drug Profile
- Product Description
- Mechanism Of Action
- BPO-27 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cholera (whole cell) vaccine - Drug Profile
- Product Description
- Mechanism Of Action
- cholera [serotypes O1 + O139] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

cholera [strain O1/EI/Tor/Ogawa] vaccine - Drug Profile

Product Description

Mechanism Of Action

cholera [strains O1 Inaba + O1 Ogawa] (whole cell) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

cholera strain [CVD 103-HgR] vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

cholera vaccine - Drug Profile

Product Description

Mechanism Of Action

cholera vaccine - Drug Profile

Product Description

Mechanism Of Action

Cholvax - Drug Profile

Product Description

Mechanism Of Action

History of Events

crofelemer DR - Drug Profile

Product Description

Mechanism Of Action

History of Events

IMSUTMR-1501 - Drug Profile

Product Description

Mechanism Of Action

History of Events

LB-2 - Drug Profile

Product Description

Mechanism Of Action

Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

Cholera - Dormant Projects

Cholera - Discontinued Products

Cholera - Product Development Milestones

Featured News & Press Releases

Jan 28, 2021: CHMP recommended extensions of indication for Vaxchora

Jan 31, 2020: Emergent BioSolutions receives positive CHMP opinion for Vaxchora; anticipates near-term approval by European Medicines Agency

Oct 28, 2019: IVI awarded \$4.5 million grant to increase accessibility of oral cholera vaccine

Jun 04, 2019: Emergent BioSolutions announces FDA approval of change in storage conditions and transfer of manufacturing for its cholera vaccine

Jun 13, 2018: Fast-acting Cholera Vaccine Could Curb Outbreaks

Dec 11, 2017: PaxVax: Single-dose vaccine could provide faster protection in cholera epidemics

Dec 06, 2017: Randomized Placebo-Controlled Study Provides Encouraging Results for a Higher Dose Formulation of Vaxchora (CVD 103-HgR) as a Potential Tool in Containing Cholera Epidemics

Oct 12, 2017: Hilleman Labs achieves successful outcome of Phase I/II Clinical Trial of its Oral Cholera Vaccine Hillchol

Oct 01, 2017: Hilleman Laboratories awarded global patents for Oral Cholera Vaccine

Sep 28, 2017: Hilleman Laboratories receives Indo-Swedish grant for developing - Oral Cholera Vaccine (OCV)

Oct 24, 2016: PaxVax's Vaxchora Now Available as the Only U.S. Approved Vaccine for Protection Against Cholera

Jun 23, 2016: CDC Advisory Committee On Immunization Practices Votes To Recommend Vaxchora, PaxVax's Single-Dose Oral Cholera Vaccine

Jun 20, 2016: FDA Approves PaxVax to Manufacture Vaxchora (Oral Cholera Vaccine) at SynCo Bio Partners

Jun 10, 2016: FDA approves vaccine to prevent cholera for travelers

Apr 27, 2016: Hilleman Laboratories advances two vaccines into clinical stage

Appendix

Methodology

Coverage

Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cholera, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Cholera - Pipeline by Bharat Biotech Ltd, 2022
Cholera - Pipeline by Emergent BioSolutions Inc, 2022
Cholera - Pipeline by Global BioLife Inc Ltd, 2022
Cholera - Pipeline by Napo Pharmaceuticals Inc, 2022
Cholera - Pipeline by Ostrich Pharma USA Inc, 2022
Cholera - Pipeline by SOM Biotech SL, 2022
Cholera - Pipeline by Vanda Pharmaceuticals Inc, 2022
Cholera - Dormant Projects, 2022
Cholera - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cholera, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Cholera Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CE290E1A2351EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CE290E1A2351EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

